Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2023 Apr 11;49(1):45.
doi: 10.1186/s13052-023-01451-6.

The therapeutic window of intravenous immunoglobulin (IVIG) and its correlation with clinical outcomes in Kawasaki disease: a systematic review and meta-analysis

Zheng Li #  1 , Jianghui Cai #  2 , Jing Lu #  1 , Mingju Wang #  1 , Chenmei Yang  1 , Zheng Zeng  1 , Qian Tang  1 , Jianhong Li  1 , Wen Tang  1 , Huiling Luo  1 , Gaofeng Pan  1 , Xingmao Zeng  3   4
Affiliations
Meta-Analysis

The therapeutic window of intravenous immunoglobulin (IVIG) and its correlation with clinical outcomes in Kawasaki disease: a systematic review and meta-analysis

Zheng Li et al. Ital J Pediatr. .

Abstract

Background: The optimal therapeutic window to start intravenous immunoglobulin (IVIG) for Kawasaki disease (KD) is highly debatable. We aimed to summarize the existing literature to evaluate the therapeutic window of IVIG treatment and its correlation with clinical outcomes in KD patients.

Methods: We searched the databases from inception to August 26, 2022, without language restrictions. The primary outcomes were initial IVIG resistance and coronary artery lesions (CALs) in acute phase. Secondary outcome was CALs during 1-2 months of follow-up.

Results: 27 studies involving 41,139 patients were included in this study. Very low-quality evidence showed that the earlier IVIG treatment within 4 days had a higher IVIG-resistance rate (RR, 1.80; 95% CI, 1.50-2.15; P < .00001; I2 = 75%) than the late treatment. Very low-quality evidence showed that IVIG treatment for more than 7 days was associated with a higher risk of CALs in acute phase(RR, 0.57; 95% CI, 0.40-0.80; P = .001; I2 = 76%). There was a lower risk of CALs during 1-2 months follow-up for those who started IVIG administration within 10 days from the onset.

Conclusions: Overall, IVIG treatment within 7 days of illness seems to be the optimal therapeutic window of IVIG. IVIG treatment within 7 days is found to be effective for reducing the risk of coronary artery lesions and cardiac sequelae in KD patients. The early IVIG treatment within 4 days should be vigilant for the IVIG resistance although large multi-center randomized trials with well design are needed.

Keywords: CALs; IVIG; IVIG resistance; Intravenous immunoglobulin; Kawasaki disease.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflict of interest to declare.

Figures

Fig. 1
Fig. 1
PRISMA Flow Diagram
Fig. 2
Fig. 2
Forest Plot of risk ratios for initial IVIG resistance for Early IVIG VS. Late IVIG.
Fig. 3
Fig. 3
Forest Plot of risk ratios for CALs in the acute phase for Early IVIG VS. Late IVIG.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. McCrindle BW, Rowley AH, Newburger JW, Burns JC, Bolger AF, Gewitz M, et al. Diagnosis, treatment, and long-term management of Kawasaki Disease: A Scientific Statement for Health Professionals from the American Heart Association. Circulation. 2017;135:e927–99. doi: 10.1161/CIR.0000000000000484. - DOI - PubMed
    1. Zhang Y, Wang X, Cai J, Yang Y, Liu Y, Liao Y, et al. Status and influencing factors of medication literacy among chinese caregivers of discharged children with Kawasaki disease. Front Public Health. 2022;10:960913. doi: 10.3389/fpubh.2022.960913. - DOI - PMC - PubMed
    1. Lucas R, Dennington P, Wood E, Murray KJ, Cheng A, Burgner D, et al. Epidemiology of Kawasaki disease in Australia using two nationally complete datasets. J Paediatr Child Health. 2022;58:674–82. doi: 10.1111/jpc.15816. - DOI - PubMed
    1. Matsubara Y, Matsubara D, Ae R, Kosami K, Aoyama Y, Yashiro M, et al. Cumulative incidence of Kawasaki disease with cardiac sequelae in Japan. Pediatr Int. 2020;62:444–50. doi: 10.1111/ped.14164. - DOI - PubMed
    1. Masuda H, Ae R, Koshimizu TA, Matsumura M, Kosami K, Hayashida K, et al. Epidemiology and risk factors for giant coronary artery aneurysms identified after Acute Kawasaki Disease. Pediatr Cardiol. 2021;42:969–77. doi: 10.1007/s00246-021-02571-8. - DOI - PubMed

MeSH terms

Substances